The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cardiovascular Drugs and Therapy

• Publication date

  2015-11-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10557-015-6629-yPMID 26602563
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of Vitamin D Supplementation on Arterial Vasomotion, Stiffness and Endothelial Biomarkers in Chronic Kidney Disease Patients

  2014cited by this paper
• Vitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic rats.

  2014cited by this paper
• Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.

  2014cited by this paper
• Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis.

  2013cited by this paper
• Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3

  2012cited by this paper
• UPDATE ON FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE

  2012cited by this paper
• Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.

  2012cited by this paper
• FGF23 induces left ventricular hypertrophy.

  2011cited by this paper
• Cardiomyocyte-Specific Deletion of the Vitamin D Receptor Gene Results in Cardiac Hypertrophy

  2011cited by this paper
• Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

  2011cited by this paper
• Oxidative and Nitrosative Stress and Progression of Diabetic Nephropathy in Type 2 Diabetes

  2010cited by this paper
• Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

  2010cited by this paper
• Parathyroid hormone accelerates decompensation following left ventricular hypertrophy

  2010cited by this paper
• Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies.

  2010cited by this paper
• Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.

  2010cited by this paper
• Calcium, vitamin D and dairy intake in relation to type 2 diabetes risk in a Japanese cohort

  2009cited by this paper
• Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

  2009cited by this paper
• Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress.

  2009cited by this paper
• Chronic kidney disease, hypovitaminosis D, and mortality in the United States.

  2009cited by this paper
• Significant vitamin D deficiency in youth with type 1 diabetes mellitus.

  2009cited by this paper
• Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options.

  2008cited by this paper
• MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets.

  2008cited by this paper
• Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels

  2008cited by this paper
• Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

  2008cited by this paper
• Vitamin D deficiency.

  2007cited by this paper
• Relationship between parathyroid hormone and cardiac abnormalities in chronic dialysis patients.

  2007cited by this paper
• Diabetic cardiomyopathy revisited.

  2007cited by this paper
• Decreased cardiac sarcoplasmic reticulum Ca2+-ATPase activity contributes to cardiac dysfunction in streptozotocin-induced diabetic rats

  2006cited by this paper
• Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation.

  2006cited by this paper
• Pleiotropic Effects of the β-Adrenoceptor Blocker Carvedilol on Calcium Regulation during Oxidative Stress-Induced Apoptosis in Cardiomyocytes

  2006cited by this paper
• Review: the renoprotective effects of ACE inhibitors and ARBs independent of blood pressure control are uncertain

  2006cited by this paper
• Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

  2005cited by this paper
• The oxidant and antioxidant effects of 25-hydroxyvitamin D3 in liver, kidney and heart tissues of diabetic rats

  2005cited by this paper
• Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study.

  2005cited by this paper
• Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.

  2004cited by this paper
• Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

  2004cited by this paper
• β-Adrenoceptor Blocker Carvedilol Provides Cardioprotection via an Adenosine-Dependent Mechanism in Ischemic Canine Hearts

  2004cited by this paper
• Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey.

  2004cited by this paper
• Control of Cardiac Growth and Function by Calcineurin Signaling*

  2003cited by this paper
• Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study

  2002cited by this paper
• Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats.

  2002cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

  2002cited by this paper
• Defective intracellular Ca2+ signaling contributes to cardiomyopathy in Type 1 diabetic rats

  2002cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Effect of Intravenous Calcitriol on Cardiac Systolic and Diastolic Function in Patients on Hemodialysis

  1998cited by this paper
• New type of cardiomyopathy associated with diabetic glomerulosclerosis.

  1972cited by this paper

• Potential Actions of Baicalein for Preventing Vascular Calcification of Smooth Muscle Cells In Vitro and In Vivo

  2022cites this paper
• Evaluation of Serum Vitamin D3 Levels and Factors Associated with Chronic Hepatitis B: A Case-Control Study

  2022cites this paper
• In uence of Coexisting Chronic Kidney Disease and Left Ventricular Hypertrophy on Changes in FGF23 and the Renin-Angiotensin-Aldosterone- System

  2021cites this paper
• Influence of oxidative stress on vascular calcification in the setting of coexisting chronic and

  2021cites this paper
• Evaluation between vitamin D serum level and Herpes Simplex Virus Type 1 in the field of dentistry

  2021cites this paper
• Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy

  2021cites this paper
• Influence of oxidative stress on vascular calcification in the setting of coexisting chronic kidney disease and diabetes mellitus

  2020cites this paper
• Resistin as a predictor of cardiovascular hospital admissions and renal deterioration in diabetic patients with chronic kidney disease.

  2019cites this paper
• FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction.

  2019cites this paper
• Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases

  2018cites this paper
• Vitamin D deficiency and hepatitis viruses-associated liver diseases: A literature review

  2018cites this paper
• Role of Vitamin D in Cardiovascular Diseases.

  2017cites this paper
• Mineral metabolism and cardiovascular disease in CKD

  2017cites this paper
• Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.

  2017cites this paper
• Vitamin D and K signaling pathways in hepatocellular carcinoma.

  2017cites this paper
• Association of vitamin D deficiency with hepatitis B virus - related liver diseases

  2016cites this paper